Rituximab

Tomohiro Kinoshita, Akihiro Tomita

Research output: Contribution to journalArticle

Abstract

Rituximab is a chimeric anti-CD20 monoclonal antibody. CD20 is a cell-surface protein that occurs almost exclusively on mature B-cells. The main mechanisms of its actions are complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), and induction of apoptosis. It is highly effective in the treatment of CD20-positive B-cell lymphoma such as follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). Rituximab can be easily combined with conventional combination chemotherapies such as cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP). Rituximab with CHOP (R-CHOP) could improve the survival of DLBCL, and R-CHOP was established as a standard treatment for DLBCL As for FL, the use of combining rituximab with chemotherapy was superior to chemotherapy alone, and is considered standard treatment. Also rituximab maintenance therapy could improve the treatment results of patients with FL who were treated with rituximab monotherapy, combination chemotherapies and rituximab-containing chemotherapies. Some patients with B-cell lymphoma are resistant to rituximab, and the mechanisms remain to be elucidated. We found that some B-cell lymphoma cells lost their CD20 expression at relapse or progression after rituximab treatment. We have successfully established a B-cell line from a patient with B-cell lymphoma who showed CD20-negative relapse after rituximab treatment. The expressions of CD20 mRNA and protein in this cell line were stimulated when the cells were treated with 5-aza-2′-deoxycytidine (decitabine). These findings suggest that some epigenetic mechanisms may be partly related to the down regulation of CD20 expression after rituximab treatment. Further studies on the mechanisms of CD20-negative relapse will overcome the rituximab-resistance in some B-cell lymphoma patients.

Original languageEnglish
Pages (from-to)67-70
Number of pages4
JournalBiotherapy
Volume24
Issue number1
Publication statusPublished - 01-01-2010
Externally publishedYes

Fingerprint

B-Cell Lymphoma
decitabine
Follicular Lymphoma
Lymphoma, Large B-Cell, Diffuse
Therapeutics
Combination Drug Therapy
Recurrence
Drug Therapy
Rituximab
B-Lymphocytes
Antibody-Dependent Cell Cytotoxicity
Cell Line
Vincristine
Prednisolone
Epigenomics
Doxorubicin
Cyclophosphamide
Membrane Proteins
Down-Regulation
Monoclonal Antibodies

All Science Journal Classification (ASJC) codes

  • Cancer Research
  • Oncology

Cite this

Kinoshita, T., & Tomita, A. (2010). Rituximab. Biotherapy, 24(1), 67-70.
Kinoshita, Tomohiro ; Tomita, Akihiro. / Rituximab. In: Biotherapy. 2010 ; Vol. 24, No. 1. pp. 67-70.
@article{3caead89cfd84251b8c4e83fad5a7812,
title = "Rituximab",
abstract = "Rituximab is a chimeric anti-CD20 monoclonal antibody. CD20 is a cell-surface protein that occurs almost exclusively on mature B-cells. The main mechanisms of its actions are complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), and induction of apoptosis. It is highly effective in the treatment of CD20-positive B-cell lymphoma such as follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). Rituximab can be easily combined with conventional combination chemotherapies such as cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP). Rituximab with CHOP (R-CHOP) could improve the survival of DLBCL, and R-CHOP was established as a standard treatment for DLBCL As for FL, the use of combining rituximab with chemotherapy was superior to chemotherapy alone, and is considered standard treatment. Also rituximab maintenance therapy could improve the treatment results of patients with FL who were treated with rituximab monotherapy, combination chemotherapies and rituximab-containing chemotherapies. Some patients with B-cell lymphoma are resistant to rituximab, and the mechanisms remain to be elucidated. We found that some B-cell lymphoma cells lost their CD20 expression at relapse or progression after rituximab treatment. We have successfully established a B-cell line from a patient with B-cell lymphoma who showed CD20-negative relapse after rituximab treatment. The expressions of CD20 mRNA and protein in this cell line were stimulated when the cells were treated with 5-aza-2′-deoxycytidine (decitabine). These findings suggest that some epigenetic mechanisms may be partly related to the down regulation of CD20 expression after rituximab treatment. Further studies on the mechanisms of CD20-negative relapse will overcome the rituximab-resistance in some B-cell lymphoma patients.",
author = "Tomohiro Kinoshita and Akihiro Tomita",
year = "2010",
month = "1",
day = "1",
language = "English",
volume = "24",
pages = "67--70",
journal = "Biotherapy",
issn = "0914-2223",
publisher = "Gan To Kagaku Ryohosha",
number = "1",

}

Kinoshita, T & Tomita, A 2010, 'Rituximab', Biotherapy, vol. 24, no. 1, pp. 67-70.

Rituximab. / Kinoshita, Tomohiro; Tomita, Akihiro.

In: Biotherapy, Vol. 24, No. 1, 01.01.2010, p. 67-70.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Rituximab

AU - Kinoshita, Tomohiro

AU - Tomita, Akihiro

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Rituximab is a chimeric anti-CD20 monoclonal antibody. CD20 is a cell-surface protein that occurs almost exclusively on mature B-cells. The main mechanisms of its actions are complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), and induction of apoptosis. It is highly effective in the treatment of CD20-positive B-cell lymphoma such as follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). Rituximab can be easily combined with conventional combination chemotherapies such as cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP). Rituximab with CHOP (R-CHOP) could improve the survival of DLBCL, and R-CHOP was established as a standard treatment for DLBCL As for FL, the use of combining rituximab with chemotherapy was superior to chemotherapy alone, and is considered standard treatment. Also rituximab maintenance therapy could improve the treatment results of patients with FL who were treated with rituximab monotherapy, combination chemotherapies and rituximab-containing chemotherapies. Some patients with B-cell lymphoma are resistant to rituximab, and the mechanisms remain to be elucidated. We found that some B-cell lymphoma cells lost their CD20 expression at relapse or progression after rituximab treatment. We have successfully established a B-cell line from a patient with B-cell lymphoma who showed CD20-negative relapse after rituximab treatment. The expressions of CD20 mRNA and protein in this cell line were stimulated when the cells were treated with 5-aza-2′-deoxycytidine (decitabine). These findings suggest that some epigenetic mechanisms may be partly related to the down regulation of CD20 expression after rituximab treatment. Further studies on the mechanisms of CD20-negative relapse will overcome the rituximab-resistance in some B-cell lymphoma patients.

AB - Rituximab is a chimeric anti-CD20 monoclonal antibody. CD20 is a cell-surface protein that occurs almost exclusively on mature B-cells. The main mechanisms of its actions are complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), and induction of apoptosis. It is highly effective in the treatment of CD20-positive B-cell lymphoma such as follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). Rituximab can be easily combined with conventional combination chemotherapies such as cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP). Rituximab with CHOP (R-CHOP) could improve the survival of DLBCL, and R-CHOP was established as a standard treatment for DLBCL As for FL, the use of combining rituximab with chemotherapy was superior to chemotherapy alone, and is considered standard treatment. Also rituximab maintenance therapy could improve the treatment results of patients with FL who were treated with rituximab monotherapy, combination chemotherapies and rituximab-containing chemotherapies. Some patients with B-cell lymphoma are resistant to rituximab, and the mechanisms remain to be elucidated. We found that some B-cell lymphoma cells lost their CD20 expression at relapse or progression after rituximab treatment. We have successfully established a B-cell line from a patient with B-cell lymphoma who showed CD20-negative relapse after rituximab treatment. The expressions of CD20 mRNA and protein in this cell line were stimulated when the cells were treated with 5-aza-2′-deoxycytidine (decitabine). These findings suggest that some epigenetic mechanisms may be partly related to the down regulation of CD20 expression after rituximab treatment. Further studies on the mechanisms of CD20-negative relapse will overcome the rituximab-resistance in some B-cell lymphoma patients.

UR - http://www.scopus.com/inward/record.url?scp=77249115852&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77249115852&partnerID=8YFLogxK

M3 - Article

VL - 24

SP - 67

EP - 70

JO - Biotherapy

JF - Biotherapy

SN - 0914-2223

IS - 1

ER -

Kinoshita T, Tomita A. Rituximab. Biotherapy. 2010 Jan 1;24(1):67-70.